Solid Biosciences Inc. Additional Paid in Capital, Common Stock
Solid Biosciences Inc. (SLDB) had Additional Paid in Capital, Common Stock of $1.44 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $1.44B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.39B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.14B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.13B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.44B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.39B 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $1.14B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.13B 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $1.12B 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $1.12B 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $920.61M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $907.72M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $901.35M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $893.75M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $785.20M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $782.76M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $781.13M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $776.57M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $774.45M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $691.05M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $689.42M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $687.53M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $685.01M 10-K · filed 2023-03-23 | $684.90M 10-K · filed 2022-03-14 |
| 2021-09-30 | $681.42M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $678.00M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $674.36M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $536.57M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $405.39M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $402.63M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $399.38M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $396.28M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $392.90M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $331.62M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $327.71M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $324.21M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $322.18M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $320.38M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $319.07M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |